qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
NCT: NCT06971991 · RECRUITING
Brief Summary
The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.
Frequently Asked Questions
What is qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver?
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver is a clinical trial registered under NCT06971991. Current status: RECRUITING.
What is the status of NCT06971991?
The current status of NCT06971991 (qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver) is: RECRUITING.
When did qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver start?
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver started on 2025-03-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.